Successful allogeneic bone marrow transplantation in patients with severe gram-negative sepsis and septic shock

We present two cases of successful allogeneic bone marrow transplantation in the patients with severe gram-negative sepsis and septic shock. The features of the post-transplantation period and management of patients are described.

• G.M. Galstyan Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• P.M. Makarova Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• L.A. Kuzmina Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• Ye.N. Parovichnikova Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• G.A. Klyasova Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• O.S. Pokrovskaya Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• M.Yu. Drokov Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• V.A. Novikov Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• V.V. Troitskaya Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• I.E. Kostina Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
• V.G. Savchenko Hematology Research Center, Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация

1. Morena M.T., Gatti R.A. A History of Bone Marrow Transplantation. Hematol. Oncol. Clin. 2011; 25: 1–15. DOI: https://doi.org/10.1016/j.hoc.2010.11.001
2. Wingard J.R., Majhail N.S., Brazauskas R. et al. Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation. J. Clin. Oncol. 2011; 29: 2230–9. DOI: https://doi.org/10.1200/JCO.2010.33.7212
3. Gyurkocza B., Rezvanil A., Storb R.F. Allogeneic hematopoietic cell transplantation: the state of the art. Exp. Rev. Hematol. 2010; 3(3): 285–99. DOI: https://doi.org/10.1586/ehm.10.21
4. Савченко В.Г., Любимова Л.С., Паровичникова Е.Н. и др. Трансплантации аллогенных и аутологичных гемопоэтических стволовых клеток при острых лейкозах (итоги 20-летнего опыта). Тер. арх. 2007; 79: 30–5. [Savchenko V.G., Lyubimova L.S., Parovichnikova Ye.N., et al. Transplantation of allogeneic and autologous hematopoietic stem cells in acute leukemias (summary of 20-year experience). Ter. arkh., 2007; 79: 30–5. (In Russ.)].
5. Blume K.G., Forman S.J., Appelbaum F.R. The evaluation and counseling of candidates for hematopoietic cell transplantation. Thomas’ Hematopoietic Cell Transplantation, 3rd ed. Malden: Blackwell, 2004: 449–67. DOI: https://doi.org/10.1002/9780470987070
6. Ball E.D., Lister J., Law P. Evaluation of patients before hematopoietic stem cell transplantation. Hematopoietic Stem Cell Therapy. New York: Churchill Livingstone, 2001: 225–32.
7. Majhail N.S., Rizzo J.D. Surviving the cure: long term follow up of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013: 1–7. DOI: https://doi.org/10.1038/bmt.2012.258
8. Soubani A.O., Kseibi E., Bander J.J. et al. Outcome and Prognostic Factors of Hematopoietic Stem Cell Transplantation Recipients Admitted to a Medical ICU. Chest 2004; 126(5): 1604–11. DOI: https://doi.org/10.1378/chest.126.5.1604
9. Marena C., Zecca M., Carenini M.L. et al. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect. Control Hosp. Epidemiol. 2001; 22: 510–7. DOI: https://doi.org/10.1086/501942
10. Huynh T.N., Weigt S.S., Belperio J.A., Territo M., Keane M.P. Outcome and Prognostic Indicators of Patients with Hematopoietic Stem Cell Transplants Admitted to the Intensive Care Unit. J. Transplant. 2009; 2009: 917294. DOI: https://doi.org/10.1155/2009/917294
11. Afessa B., Azoulay E. Critical Care of the Hematopoietic Stem Cell Transplant Recipient. Crit. Care Clin. 2010; 26: 133–50. DOI: https://doi.org/10.1016/j.ccc.2009.09.001
12. Degoricija V., Sharma M., Legac A. et al. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy. Croat. Med. J. 2006; 47(3): 385–97.
13. Shirazi M.H., Ranjbar R., Ghasemi A. et al. A Survey of Bacterial Infections in Bone Marrow Transplant Recipients. Iran. J. Publ. Health 2007; 36: 77–81.
14. Ali N., Adil S.M., Shaikh M.U., Moosajee M., Masood N. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exper. Hematol. Oncol. 2012; 1: 13. DOI: https://doi.org/10.1186/2162-3619-1-13
15. George B., Mathews V., Srivastava A., Chandy M. Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant. 2004; 33: 311–5. DOI: https://doi.org/10.1038/sj.bmt.1704347
16. Donnelly P. Bacterial complications of transplantation: diagnosis and treatment. J. Antimicrob. Chemother. 1995; 36: 59–72. DOI: https://doi.org/10.1093/jac/36.suppl_B.59
17. van Kraaij M.G., Dekker A.W., Verdonck L.F. et al. Infectious gastroenteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant. 2000; 26(3): 299–303. DOI: https://doi.org/10.1038/sj.bmt.1702484
18. Schulenburg A., Turetschek K., Wrba F. et al. Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation. Ann. Hematol. 2004; 83(2): 101–6. DOI: https://doi.org/10.1007/s00277-003-0756-4
19. Holler E., Kolb H.J., Greinix H. et al. Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplant. 2009; 43(6): 491–7. DOI: https://doi.org/10.1038/bmt.2008.337
20. Mikulska M., Del Bono V., Bruzzi P. et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 2012; 40: 271–8. DOI: https://doi.org/10.1007/s15010-011-0229-y
21. Legrand M., Max A., Peigne V. et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit. Care Med. 2012; 40(1): 43–9. DOI: https://doi.org/10.1097/CCM.0b013e31822b50c2
22. Reikvam H., Hatfiel K.J., Kittang A.O., Hovland R., Bruserud O. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. doi: 10.1155/2011/104631. Epub, May 3, 2011. DOI: https://doi.org/10.1155/2011/104631
23. Cho E.K., Bang S.M., Ahn J.Y. et al. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. Korean J. Intern. Med. 2003; 18(1): 13–20. DOI: https://doi.org/10.3904/kjim.2003.18.1.13
24. Программное лечение заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2012: 720–34. [Programmnoye lecheniye zabolevaniy sistemy krovi. Pod red. V.G. Sav chenko (Program therapy for hematological malignancies. Ed. by: V.G. Savchenko). M.: Praktika, 2012: 720–34.]
25. De Pauw B., Walsh T.J., Donnelly J.P. et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008; 46(12): 1813–21. DOI: https://doi.org/10.1086/588660
26. Afessa B., Tefferi A., Dunn W.F. et al. Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients. Crit. Care Med. 2003; 31(6): 1715–21. DOI: https://doi.org/10.1097/01.CCM.0000065761.51367.2D
27. Leung A.N., Gosselin M.V., Napper C.H. et al. Pulmonary Infections after Bone Marrow Transplantation: Clinical and Radiographic Findings. Radiology 1999; 210: 699–710. DOI: https://doi.org/10.1148/radiology.210.3.r99mr39699
28. Champlin R.E., Perez W.S., Passweg J.R. et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109(10): 4582–5. DOI: https://doi.org/10.1182/blood-2006-10-052308
29. Georges G.E., Storb R. Stem cell transplantation for aplastic anemia. Int. J. Hematol. 2002; 75(2): 141–6. DOI: https://doi.org/10.1007/BF02982018
30. Quenot J.P., Binquet C., Kara F., Martinet O. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit. Care. 2013; 17: R65. DOI: https://doi.org/10.1186/cc12598
31. Jawad I., Luksic I., Rafnsson S.B. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. Glob. Health 2012; 2(1): 10404. DOI: https://doi.org/10.7189/jogh.01.010404
32. Ghosh I., Raina V., Kumar L. et al. Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med. Oncol. 2012; 29: 1354–60. DOI: https://doi.org/10.1007/s12032-011-9858-3
33. Klastersky J., Ameye L., Maertens J. et al. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents 2007; 30: 51–9. DOI: https://doi.org/10.1016/j.ijantimicag.2007.06.012
34. Sakamoto M., Saruta K., Nakazawa Y. et al. Sepsis Associated with Hematological Malignancies: Prophylaxis of Pseudomonas aeruginosa Sepsis. 69th General Meeting of the Japanese Association for Infectious Diseases (Fukuoka). Kansenshogaku Zasshi 1996; 70(2): 116–22. DOI: https://doi.org/10.11150/kansenshogakuzasshi1970.70.116
35. Клясова Г.А. Инфекции при гемобластозах и депрессиях кроветворения: клиника, диагностика и лечение: Автореф. дис. ¼ д-ра мед. наук. М., 2009. [Klyasova G.A. Infektsii pri gemoblastozakh i depressiyakh krovetvoreniya: klinika, diagnostika i lechenie. Dokt. diss. (Infections in hematological malignancies and depressed hematopoiesis. Dr. med. sci. diss.). M., 2009]
36. Mokart D., Craenenbroeck T. Prognosis of acute respiratory distress syndrome (ARDS) in neutropenic cancer patients. Eur. Respir. J. 2012; 40(1): 169–76. DOI: https://doi.org/10.1183/09031936.00150611
37. Regazzoni C.J., Irrazabal C., Luna C.M., Poderoso J.J. Cancer patients with septic shock: mortality predictors and neutropenia. Supp. Care Cancer 2004; 12: 833–9. DOI: https://doi.org/10.1007/s00520-004-0667-5
38. Groeger J.S., Lemeyow S., Price K., Nierman J. Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. Clin. Oncol. 1998; 16: 761–70. DOI: https://doi.org/10.1200/JCO.1998.16.2.761
39. Gronlykke L., Brandstrup S.L., Perner A. Data from clinical database on septic shock are valid. Dan. Med. J. 2012; 59(10): A4522.
40. Горелов В.Г. Эффективность искусственной вентиляции легких при острой дыхательной недостаточности у больных гемобластозами: Автореф. дис. ¼ канд. мед. наук. М., 1994. [Gorelov V.G. Effektivnost iskusstvennoy ventilyatsii legkikh pri ostroy dykhatelnoy nedostatochnosti u bolnykh gemoblastozami. Kand. diss. (Efficacy of mechanical lung ventilation in acute respiratory failure in patients with hematological malignancies. Cand med. sci.diss.). M., 1994]
41. Бычинин М.В., Галстян Г.М., Шулутко Е.М., Клясова Г.А., Городецкий В.М. Катетеризация артерий у гематологических больных. Гематол. и трансфузиол. 2013; 58: 14–22. [Bychinin M.V., Galstyan G.M., Shulutko Ye.M., Klyasova G.A., Gorodetzky V.M. Artery catheterization in hematological patients. Gematol. i transfuziol. 2013; 58: 14–22. (In Russ.)].
42. Shirley H., Mei J. Mesenchymal Stem Cells Reduce Inflammation while Enhancing Bacterial Clearance and Improving Survival in Sepsis. Am. J. Respir. Crit. Care Med. 2010; 182(8): 1047–57. DOI: https://doi.org/10.1164/rccm.201001-0010OC
43. Gilbert C., Vasu T.S., Baram M. Use of mechanical ventilation and renal replacement therapy in critically ill hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 2013; 19(2): 321–4. DOI: https://doi.org/10.1016/j.bbmt.2012.09.010
44. Azoulay E., Alberti C., Bornstain C. et al. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit. Care Med. 2001; 29(3): 519–25. DOI: https://doi.org/10.1097/00003246-200103000-00009
45. Avivi I., Oren I., Haddad N., Rowe J.M. Stem Cell Transplantation Post Invasive Fungal Infection Is a Feasible Task. Am. J. Hematol. 2004; 75: 6–11. DOI: https://doi.org/10.1002/ajh.10447
46. Bjerke J.W., Meyers J.D., Bowden R.A. Hepatosplenic candidiasis — a contraindication to marrow transplantation? Blood 1994; 84: 2811–4. DOI: https://doi.org/10.1182/blood.V84.8.2811.bloodjournal8482811
47. Wang J.T., Yao M., Tang J.L., Chang S.C., Hung C.C. Prior invasive fungal infection is not a contraindication for subsequent allogeneic bone marrow transplantation in adult patients with hematologic malignancies. J. Clin. Oncol. 2001; 19(1): 4000–1. DOI: https://doi.org/10.1200/JCO.2001.19.19.4000
48. Aki Z.S., Sucak G.T., Yegin Z.A. et al. Hematopoietic Stem Cell Transplantation in Patients With Active Fungal Infection: Not a Contraindication for Transplantation. Transplant. Proceed. 2008; 40: 1579–85. DOI: https://doi.org/10.1016/j.transproceed.2008.03.149
49. El-Cheikh J., Castagna L., Wang L. et al. Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk. Lymphoma 2010; 51(9): 1705–10. DOI: https://doi.org/10.3109/10428194.2010.500433
50. Lee J.Y., Jung C.W., Kim K., Jang J.H. Impact of previous invasive pulmonary aspergillosis on the outcome of allogeneic hematopoietic stem cell transplantation. Korean J. Hematol. 2012; 47(4): 255–9. DOI: https://doi.org/10.5045/kjh.2012.47.4.255
51. Dellinger R.P., Levy M.M., Rhodes A. et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intens. Care Med. 2013; 39(2): 165–228. DOI: https://doi.org/10.1007/s00134-012-2769-8
52. Pittenger M.F., Mackay A.M., Beck S.C. et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–7. DOI: https://doi.org/10.1126/science.284.5411.143
53. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 2000; 28: 875–84. DOI: https://doi.org/10.1016/S0301-472X(00)00482-3
54. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008; 36: 733–41. DOI: https://doi.org/10.1016/j.exphem.2008.03.006
55. Петинати Н.А. Профилактика реакции трансплантат против хозяина у больных гемобластозами после трансплантации аллогенных гемопоэтических стволовых клеток с помощью мультипотентных мезенхимальных стромальных клеток донора: Автореф. дис. ¼ канд. мед. наук. М., 2013. [Petinati N.A. Profilaktika reaktsii transplantat protiv khozyaina u bolnykh gemoblastozami posle transplantatsii allogennykh gemopoeticheskikh stvolovykh kletok s pomoshchyu multipotentnykh mezenkhimalnykh stromalnykh kletok donora. Kand. diss. (Prevetion of graft-versus-host disease in patients with hematological malignancies after transplantation of allogeneic hematopoietic stem cells using multipotent mesenchymal stromal donor cells. Cand med. sci. diss.). M., 2013].
56. Kuzmina L.A., Petinati N.A., Parovichnikova E.N. et al. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease — A Phase II Study. Stem Cells Int. 2012; 2012: 968213. DOI: https://doi.org/10.1155/2012/968213
57. Kebriaei P., Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011; 13(3): 262–8. DOI: https://doi.org/10.3109/14653249.2010.549688
58. Lucchini G., Dander E., Rovelli A. et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graftversus-host disease in a pediatric population. Biol. Blood Marrow Transplant. 2010; 16: 1293–301. DOI: https://doi.org/10.1016/j.bbmt.2010.03.017
59. Toubai Т., Paczesny S., Shono Y. et al. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Curr. Stem Cell Res. Ther. 2009; 4: 252–9. DOI: https://doi.org/10.2174/157488809789649269
60. Osuchowski M.F., Welch K., Siddiqui J., Remick D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the sirs/cars continuum in sepsis and predict mortality. J. Immunol. 2006; 177: 1967–74. DOI: https://doi.org/10.4049/jimmunol.177.3.1967
61. Chien M.H., Bien M.Y., Ku C.C. et al. Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation in lipopolysaccharide-induced acute lung injury. Crit. Care Med. 2012; 40(4): 1245–53. DOI: https://doi.org/10.1097/CCM.0b013e31823bc89a
62. Kim E.S., Sil Y. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli induced acute lung injury in mice. Respir. Res. 2011; 12: 108. DOI: https://doi.org/10.1186/1465-9921-12-108
63. Adult stem cell transplantation in severe blood poisoning. 2011-MSC-1 Erasmus MC Rotterdam. http://www.trialregister.nl/ 64. OHRI, Ottawa to lead first stem cell therapy trial for septic shock/2012. http://nationalhealthwatch.ca/